Changes in Beneficial Ownership · 4

Agenus Inc.

AGENNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 12, 2026Accepted Aug 12, 2026, 9:30 PM EDTFiling CIK 1098972Accession 0001193125-26-347517

View company →Permanent SEC source ↗

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period: 2026-08-10
Issuer: AGENUS INC
Issuer CIK: 0001098972
Trading symbol: AGEN

Reporting owner 1

Name: ARMEN GARO H
Reporting owner CIK: 0000935679
Relationship: Director · Officer
Officer title: See Remarks
Address: C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421

Derivative transactions

Derivative transactions · 1 reported row
Security	Conversion / exercise price (USD)	Transaction date	Code	Amount	A / D	Price (USD)	Exercisable	Expires	Underlying security	Underlying shares	Owned after	Ownership
Stock Option	7.78	2026-08-10	A · Form 4	1,971,500	A	0.00	^[F1]	2036-08-10	Common Stock	1,971,500	1,971,500	D

Table key

A · Form 4: Acquisition by grant, award or otherwise under Rule 16b-3(d)
A: Acquired
D: Direct

Footnotes

F1: Option awarded in accordance with the Agenus Inc. Amended and Restated 2019 Equity Incentive Plan. The options are divided into five equal tranches, each of which vests only if the Company's stock price achieves and sustains, for 30 consecutive calendar days during the five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x, respectively, of the measurement price of $7.78 per share, subject in each case to a minimum three-year service requirement.↩ 1

Remarks

Chairman, Chief Executive Officer and Principal Financial Officer

Signature 1

Signed: /s/ Melissa Orilall, as Attorney-in-Fact for Garo H. Armen
Date: 2026-08-12

Company context

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Current securities

AGENNASDAQ · EQUITY · Current

Get the free weekly BCS email.